Elena Kalinichenko told the journalists that the NASB Institute of Bioorganic Chemistry registered the first original drug Leykovir for treatment of patients suffering from multiple sclerosis. She explained that the disease, when progressing, led to complete disability of a person, and the drug could stop the process of destruction of certain areas, inflamed in the brain.
Olga Kazyuchits reported that the Akadempharm completed the year worthily. In 2018, the company will let out products worth Br21 million.
Zoya Kuvaeva informed the media about the work of the NASB Institute of Physical and Organic Chemistry on the development of new drugs based on the compositions of amino acids and their derivatives.
The participants of the press event answered the journalists' questions.